PaclitaxelTaxoidsAntineoplastic Agents, PhytogenicBridged CompoundsAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleBreast NeoplasmsEpothilonesAntineoplastic AgentsAnthracyclinesTubulin ModulatorsDrug Resistance, NeoplasmDeoxycytidineCarboplatinTreatment OutcomeCisplatinInfusions, IntravenousLung NeoplasmsMaximum Tolerated DoseOvarian NeoplasmsTaxusAntimitotic AgentsNeutropeniaCarcinoma, Non-Small-Cell LungFluorouracilVinblastineDoxorubicinDose-Response Relationship, DrugEpirubicinDisease-Free SurvivalCell Line, TumorTubulinChemotherapy, AdjuvantCorylusNeoplasm MetastasisSurvival AnalysisNeoplasmsPlatinum CompoundsAntibodies, Monoclonal, HumanizedProstatic NeoplasmsDrug SynergismEstramustineMicrotubulesDrug Screening Assays, AntitumorVinca AlkaloidsSurvival RateNeoplasm StagingCombined Modality TherapyFluorine CompoundsClinical Trials, Phase III as TopicXenograft Model Antitumor AssaysArea Under CurveP-GlycoproteinSalvage TherapyCyclophosphamideMice, NudeNeoadjuvant TherapyApoptosisReceptor, erbB-2AstheniaLeukopeniaClinical Trials, Phase II as TopicDisease ProgressionPeripheral Nervous System DiseasesTumor Cells, CulturedAdenocarcinomaNeoplasm Recurrence, LocalOxonic AcidAntibiotics, AntineoplasticAdministration, OralPharmaceutical VehiclesCarcinomaOrganoplatinum CompoundsAntibodies, MonoclonalFallopian Tube NeoplasmsGranulocyte Colony-Stimulating FactorQuinazolinesClinical Trials, Phase I as TopicAlopeciaMitosisTime FactorsTegafurStomach NeoplasmsNoscapineCell SurvivalPeritoneal NeoplasmsClinical Trials as TopicCell ProliferationP-GlycoproteinsRadiation-Sensitizing AgentsRandomized Controlled Trials as TopicAngiogenesis InhibitorsFeasibility StudiesHematologic DiseasesTopotecanCell CycleAntimetabolites, AntineoplasticDrug Delivery SystemsMitoxantroneGenes, erbB-2